Please login to order a test.
Crohn's Disease Prognostic Profile
Prognostic aid for use in the clinical management of patients who have been diagnosed with Crohn's disease.
The absence of antibody reactivity in this panel, although associated with increased incidence of a more benign course, does not preclude the future development of more complicated disease or need for surgery.1
Enzyme immunoassay (EIA)
The presence and increasing titer of these antibodies has been shown to correlate with a more complicated disease course (strictures or fistulas) or the need for surgery. The antibodies included in the panel are ASCA (anti-Saccharomyces cerevisiae antibodies), ALCA (antilaminaribioside carbohydrate antibodies), ACCA (antichitobioside carbohydrate antibodies), and AMCA (antimannobioside carbohydrate antibodies).1-3 Numerous studies of CD have demonstrated an association between ileal disease and the presence of ASCA,1-7 ACCA,1 ALCA,1,3 and AMCA.3 Among these antibodies, the association with localization to the small intestine increased with the number of positive antibodies and with the concentration of individual antibodies.1-3,6,8 A more aggressive or complicated disease course in CD (as indicated by stricturing or perforation of the intestine or need of surgery), has also been associated with the presence of ASCA,1-3,5,7 ALCA,1-3 ACCA,1,2 and AMCA.1,2 Among these antibodies, the association with complicated disease behavior or surgery increased with the number and concentration of antibodies.1,2,6,8
Causes for Rejection
|Order Code||Order Code Name||Order Loinc||Result Code||Result Code Name||UofM||Result LOINC|
|162020||Crohn's IBDX Prognostic Panel||53598-9||162021||gASCA||units||47321-5|
|162020||Crohn's IBDX Prognostic Panel||53598-9||162022||ACCA||units||53594-8|
|162020||Crohn's IBDX Prognostic Panel||53598-9||162023||ALCA||units||53596-3|
|162020||Crohn's IBDX Prognostic Panel||53598-9||162025||AMCA||units||53597-1|